<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04506060</url>
  </required_header>
  <id_info>
    <org_study_id>PI2020_843_0101</org_study_id>
    <nct_id>NCT04506060</nct_id>
  </id_info>
  <brief_title>Evaluation of Renal Pretransplant Serology for BK Virus on the Risk of Post-transplant Viral Reactivation</brief_title>
  <acronym>BKSEREIN</acronym>
  <official_title>Evaluation of Renal Pretransplant Serology for BK Virus on the Risk of Post-transplant Viral Reactivation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire, Amiens</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Due to the increasing importance of BKV infection on the survival of kidney transplants, a&#xD;
      better knowledge, in the pretransplant phase, of the risk factors leading to viral&#xD;
      reactivation could allow the follow-up physician to be more vigilant and better prevent this&#xD;
      pathology. There are no commercial tests for BKV serology. In the virology laboratory, the&#xD;
      investigators have developed the technique for producing &quot;Virus-like particles&quot; (VLP) that&#xD;
      mimics the antigenic structure of the BK virus. The investigators plan to evaluate&#xD;
      seroreactivity to the five BK virus serotypes in the recipient of a kidney transplant as a&#xD;
      pretransplant and to compare this data with the detection or not of viral reactivation in the&#xD;
      recipient during the first post-transplant year.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2020</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Serum antibody titre limit measurement of the five BK virus serotypes in pre-transplant patient</measure>
    <time_frame>one year</time_frame>
    <description>Serum antibody titre limit measurement of the five BK virus serotypes in pre-transplant patient. Optical density of serum antibody titer will be obtained by Elisa.</description>
  </primary_outcome>
  <enrollment type="Anticipated">378</enrollment>
  <condition>BK Virus Nephropathy</condition>
  <condition>Risk Factor</condition>
  <condition>Kidney Transplantation</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>serum withdrawal</intervention_name>
    <description>Serum of the transplant patient. In the transplanted patient, the search for the BK virus is traditionally carried out during visits in the first year after transplantation.</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum of the transplant patient. In the transplanted patient, the search for the BK virus is&#xD;
      traditionally carried out during visits in the first year after transplantation.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Renal transplant patients with regular virological follow-up (blood and urine for BKV)&#xD;
        during the first year after transplantation&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  adult kidney transplanted patients&#xD;
&#xD;
          -  Renal transplant patients with regular virological follow-up (blood and urine for BKV)&#xD;
             during the first year after transplantation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Renal transplant patients with no follow-up for one year after transplantation&#xD;
             (transplant failure, return to dialysis, death, follow-up outside the transplant&#xD;
             centre)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Etienne Brochot, MD</last_name>
    <phone>(33)322087064</phone>
    <email>brochot.etienne@chu-amiens.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80480</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Etienne Brochot, MD</last_name>
      <phone>(33)322087064</phone>
      <email>brochot.etienne@chu-amiens.fr</email>
    </contact>
    <contact_backup>
      <last_name>Etienne Brochot</last_name>
      <phone>(33)322087064</phone>
      <email>brochot.etienne@chu-amiens.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Mait√© Jaureguy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>August 6, 2020</study_first_submitted>
  <study_first_submitted_qc>August 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2020</study_first_posted>
  <last_update_submitted>July 20, 2021</last_update_submitted>
  <last_update_submitted_qc>July 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BK Virus Nephropathy</keyword>
  <keyword>risk factor</keyword>
  <keyword>kidney transplantation</keyword>
  <keyword>viral serology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

